[Platelet aggregation in hyperlipoproteinemias].
The Authors studied platelet aggregation in 42 hyperlipoproteinemic patients (10 with type IIA familiar, 7 with type IIA, 7 with type IIB, 18 with type IV and V). None of them suffered from clinically detectable vascular complications. The control group included 42 normolipoproteinemic subjects, closely matched for age and sex. Platelet aggregation, according Born's method, was statistically increased in hyperlipoproteinemia type IIA, but only when induced by epinephrine as aggregating agent. No statistical significance was demonstrated when hyperlipoproteinemic smokers and no smokers were compared. A positive family history of myocardial infarction and/or diabetes mellitus could be demonstrate affect on platelet aggregation.
D000293:Adolescent; D000328:Adult; D002784:Cholesterol / Q000097:blood; D003920:Diabetes Mellitus / Q000097:blood / Q000235:genetics; D004837:Epinephrine / Q000494:pharmacology; D005260:Female; D006801:Humans; D006951:Hyperlipoproteinemias / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood / Q000235:genetics; D010974:Platelet Aggregation / Q000187:drug effects; D014280:Triglycerides / Q000097:blood
D014280:Triglycerides; D002784:Cholesterol; D004837:Epinephrine
L'aggregabilità piastrinica nelle iperlipoproteinemie.